# Aulos Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aulos-bioscience

- Industry: Biotechnology
- Headquarters: Larkspur, US
- Website: www.aulosbio.com
- Total disclosed funding: $20M
- Latest round: Series A (Jul 28, 2023)
- Investors on record: 1

## About

Aulos Bioscience, based in Massachusetts, is focused on developing innovative therapeutics to transform cancer care, particularly through its lead product, AU-007, an immune-activating monoclonal antibody.Founded in 2020 in Larkspur, US, Aulos Bioscience specializes in cancer therapeutics. The firm has secured a total of USD 5.00 mn in funding, with its most recent Series A round completed on July 28, 2023, led by Apple Tree Partners. The founders include Micah Pearlman, Michael Ehlers, and Yanay Ofran, with Aron Knickerbocker serving as CEO. The company has conducted 2 deals to date, with a current valuation of USD 99.068 mn.Aulos Bioscience specializes in developing AU-007, an immune-activating monoclonal antibody aimed at enhancing anti-tumor immune responses. AU-007 targets the interaction between interleukin-2 and the CD25 receptor on regulatory T cells, seeking to minimize severe side effects of traditional therapies. The firm is advancing AU-007 through clinical trials, focusing on advanced solid tumor cancers such as melanoma and renal cell carcinoma, primarily serving oncologists, hospitals, and cancer treatment centers in North America and Europe.Aulos Bioscience generates revenue through the development and potential commercialization of AU-007. The company collaborates with healthcare institutions and clinical research organizations for patient enrollment and data collection during clinical trials. Revenue may arise from partnerships with pharmaceutical companies involving milestone payments and royalties based on the product's successful development and commercialization.Following the recent Series A funding round, which raised USD 5.00 mn on July 28, 2023, Aulos Bioscience plans to allocate these resources to further develop AU-007. The company is focused on advancing its product through clinical trials and intends to explore additional markets for its therapies, particularly in North America and Europe, as development progresses.

## Funding rounds

- Series A, Jul 28, 2023, $5M — Apple Tree Partners
- Series A, Oct 30, 2020, $15M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A